Maravai ALERT: Bragar Eagel & Squire, P.C. is Investigating Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
1. Maravai LifeSciences faces class action for possible board fiduciary duty breaches. 2. Reported $3.9 million revenue recognition error led to share price drop of 21.70%. 3. Material weaknesses in financial reporting concerning revenue and goodwill impairments disclosed. 4. Class period for potential claims spans August 7, 2024, to February 24, 2025. 5. Investigation highlights misleading statements about company's operations and financial health.